Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05534802
Other study ID # TJ-IRB20220831
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 16, 2022
Est. completion date December 30, 2024

Study information

Verified date March 2024
Source Tongji Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This project explores the role and mechanism of ulinastatin in preventing cardiac dysfunction caused by cardiopulmonary bypass by reducing cardiac endothelial permeability through clinical research. Our previous basic research has found that inhibiting the TK/B1R/ARNT/MMP3/iNOS signaling axis in the acute phase of cardiac R/I can reduce the permeability of cardiac endothelial cells, reduce cardiac edema and improve cardiac function (this part has been completed) . This study intends to investigate the effects of ulinastatin on 24-hour cardiac function and prognosis in patients undergoing cardiac surgery undergoing cardiopulmonary bypass (cardiac function, inflammatory indicators, coagulation function, capillary leakage indicators, 28-day survival time, CCU time). At the same time, we observed the dynamic changes of TK/B1R/MMP3 during cardiopulmonary bypass in patients undergoing cardiac surgery and explored its relationship with prognosis, as well as the effect of ulinastatin intervention on TK/B1R/MMP3 before and after cardiopulmonary bypass.


Description:

1. Baseline Period Visit 1 (within 24 hours before surgery) - Sign informed consent - Check inclusion/exclusion criteria - Demographic data (sex, age, occupation, etc.) - Past medical history (stroke, hypertension, diabetes, dyslipidemia, coronary heart disease, diabetes, etc.) and medication history in the past 3 months - Vital signs (temperature, pulse, respiration, blood pressure) - Preoperative ECG - Preoperative echocardiography - Laboratory tests (blood routine, blood glucose, blood lipids, liver and kidney function, myocardial enzymes, blood electrolytes, coagulation function) - Concomitant therapy - Adverse events 2. Intraoperative cardiopulmonary bypass - Record vital signs and various physiological indicators in the operating room. - Routinely perform central venous puncture to establish venous access and monitor central venous pressure, and radial artery puncture to monitor invasive arterial pressure. - After general anesthesia and endotracheal intubation, routine blood chemistry and arterial blood gas analysis were performed. - After collecting the above blood samples for testing, the remaining blood was centrifuged, and the plasma was frozen at -80°C for subsequent testing (levels of CRP, IL-6, IL-10, TNF-α, TK/B1R/MMP3, etc.). - Conventional treatment group: On the basis of general anesthesia, the extracorporeal circulation circuit was routinely prefilled. Management of CPB includes blood gas acid-base electrolyte management, anticoagulation management, invasive arterial blood pressure monitoring, MAP in the range of 50-80 mmHg, hematocrit maintained at 20-25%, and non-pulsatile flow rate of 2.0-2.4 L/min/ m2. During cardiopulmonary bypass, the dose of unfractionated heparin for anticoagulation through a central venous catheter is 300-400 U/kg, with additional doses as necessary to achieve and maintain an activated coagulation time (ACT) between 480 and 600 seconds. After isolation from cardiopulmonary bypass, heparin-induced anticoagulation was reversed with protamine. Surgical procedures include coronary artery bypass grafting, heart valve replacement, aortic replacement, etc. - Ulinastatin group: On the basis of conventional treatment, administered in accordance with the instructions or previous study doses (general anesthesia with endotracheal intubation, after cardiopulmonary bypass transfer started): 10,000 U/kg Ulinastatin (Guoyao Zhunzi H19990134 , Guangdong Tianpu Biochemical Pharmaceutical Co., Ltd., Guangzhou, China) was dissolved in 50 ml of normal saline for 1 hour through central venous infusion. After cardiopulmonary bypass - operation time - Vital signs (temperature, pulse, respiration, blood pressure) - Routine blood chemistry and arterial blood gas analysis - Document vasoactive drug use 3. 24 hours, 72 hours, 7 days after surgery - Vital signs (temperature, pulse, respiration, blood pressure) - Bedside echocardiography - Laboratory tests (blood routine, blood sugar, blood lipids, liver and kidney function, myocardial enzymes, coagulation function, etc.) - After collecting the above blood samples for testing, the remaining blood is centrifuged, and the plasma is frozen at -80°C for later testing (levels of CRP, IL-6, IL-10, TNF-α, TK/B1R/MMP3, etc.) - Capillary leak indicators - Document treatment regimen (including vasoactive drug use, etc.) 4. Follow-up period - CCU time and total hospital stay - 28-day survival status The survival status of the patients was followed up, and the date of death and the cause of death should be recorded in the patients who died. 5. Research Evaluation 1) Main efficacy indicators: cardiac function (echocardiography EF, FS), inflammatory indicators (CRP, IL-6, IL-10, TNF-α), TK/B1R/MMP3 and other levels at 24h, 72h, and 7d after surgery 2) Secondary efficacy indicators: coagulation function, capillary leakage index, 28-day survival rate, CCU time, total hospital stay. 6. Patient Completion/Withdrawal from Study Finish All evaluation data of the patients 28 days after the operation were completely collected and considered as completed cases. withdraw from the study Patients will be withdrawn from the study if: - Patient selection errors - Intraoperative and postoperative cardiac arrest due to non-CPB causes - The patient has a drug allergy - Patient withdraws informed consent - Any situation in which the investigator believes that the patient should discontinue the study for safety reasons or the patient's interest - Patient lost to follow-up - other The date and reason for termination of the study must be recorded on the data collection form. At the time of study termination, patients should be assessed for their final endpoints, in addition to loss to follow-up.


Recruitment information / eligibility

Status Recruiting
Enrollment 236
Est. completion date December 30, 2024
Est. primary completion date December 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Voluntarily sign the informed consent; 2. Age =18 years old and =70 years old; 3. Patients receiving cardiopulmonary bypass 4. Patients undergoing heart valve replacement surgery, major vascular surgery, and other cardiac surgery Exclusion Criteria: 1. Severe cardiac insufficiency before surgery (EF<50%, cardiogenic shock); 2. Patients with adverse events during surgery (such as cardiac arrest, etc.); 3. Solid organ or bone marrow transplant recipients; 4. pregnant women; 5. Have a history of allergy to ulinastatin or any of its ingredients; 6. Suffering from autoimmune diseases, tumors, or received high-dose hormones, immunosuppressive drugs, etc. within 2 months; 7. The researcher judges that it is not suitable to participate in this research.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ulinastatin
On the basis of conventional treatment, according to the instructions or previous research doses (general anesthesia and tracheal intubation, after cardiopulmonary bypass transfer starts): 10,000 U/kg Ulinastatin (National Medicine Approval No. H19990134, Guangdong Tianpu Biochemical Pharmaceutical Co., Ltd. Co., Ltd., Guangzhou, China) was dissolved in 50 ml of normal saline for 1 hour and pumped through the central vein.
Other:
saline
On the basis of conventional treatment, 50 ml of normal saline for 1 hour and pumped through the central vein.

Locations

Country Name City State
China Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan Hubei

Sponsors (1)

Lead Sponsor Collaborator
Qin Zhang

Country where clinical trial is conducted

China, 

References & Publications (3)

Atal SS, Atal S. Ulinastatin - a newer potential therapeutic option for multiple organ dysfunction syndrome. J Basic Clin Physiol Pharmacol. 2016 Mar;27(2):91-9. doi: 10.1515/jbcpp-2015-0003. — View Citation

Liu Y, Wang YL, Zou SH, Sun PF, Zhao Q. Effect of high-dose ulinastatin on the cardiopulmonary bypass-induced inflammatory response in patients undergoing open-heart surgery. Chin Med J (Engl). 2020 Jun 20;133(12):1476-1478. doi: 10.1097/CM9.0000000000000 — View Citation

Xu HY, Rong XS, Wang DP, Jiang SY, Zang ZD, Xia W, Zhang F, Yan J. Effect of urinary trypsin inhibitor on inflammatory cytokines and organ function in patients with cardiopulmonary bypass. Eur Rev Med Pharmacol Sci. 2017 May;21(9):2220-2225. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Cardiac function Echocardiographic detection 24 hours
Primary Inflammatory marker Detection of CRP 24 hours
Primary Inflammatory markers Detection of IL6 24 hours
Primary TK/B1R/MMP3 signaling Detection levels of tissue kallikrein, B1R and MMP3 24 hours
Secondary Survival time Questionnaire 28 days
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06040853 - Postoperative Pain in Laparoscopic Radical Prostatectomy Surgery With Tranexamic Acid: Analgesia? Hiperalgesia? Phase 4
Not yet recruiting NCT05553496 - Assessment of Rituximab Therapeutic Response Versus Conventional Treatment Phase 2/Phase 3
Recruiting NCT04190537 - PARADOX - the Incidence of Paradoxical Reactions in Pediatric Patients Premedicated With Midazolam
Completed NCT03522532 - Dental Restorations Effect on Oxidative Status of the Gingival Crevicular Fluid N/A
Completed NCT03119454 - "Corticoid-16" in Long Term When Administered Systemically in Patients in Routine Medical Practice N/A
Unknown status NCT01614353 - Medication-taking Preferences & Practices of Patients With Chronic Conditions N/A
Completed NCT03714360 - The Effect of Tranexamic Acid. A Randomised Study of Patients Undergoing Elective Lumbar Spine Surgery. Phase 4
Recruiting NCT03352622 - Pharmacogenomic in Colombian Patients With Rheumatoid Arthritis N/A
Recruiting NCT06288841 - Efficacy and Safety of Liposomal Bupivacaine Under ERAS Concept for Postoperative Analgesia of Ultrasound-Guided QLB in Gynecologic Laparoscopic Patients: A Randomized, Single-blind, Active-Controlled Clinical Study N/A
Not yet recruiting NCT04320277 - Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study. Phase 2/Phase 3
Completed NCT03359590 - Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients Phase 2
Completed NCT05591105 - Morphine Consumption in the Obese Patients
Not yet recruiting NCT03904303 - Test of a New Gel-based Colon Cleansing Agent Compared to Moviprep Phase 1
Not yet recruiting NCT05453045 - Pharmacokinetics and Excretion of Albendazole and Its Metabolites in Saliva N/A
Completed NCT05428683 - Intravitreal Triamcinolone and Moxifloxacin Injection After Cataract Surgery N/A
Enrolling by invitation NCT02985281 - Safety and Efficacy of Gratisovir (Sofosbuvir)- Ribavirin Therapy in Pediatric Patients Phase 2/Phase 3
Recruiting NCT06222710 - Ultrasound Guiding Pharmacopuncture Therapy for Supraspinatus Tendinopathy N/A
Not yet recruiting NCT03953287 - Pharmacokinetic Study of Paracetamol. Phase 1
Recruiting NCT03622047 - Comparison of Epidural Labor Analgesia With Dexmedetomidine or Sufentanil N/A
Active, not recruiting NCT06324370 - Exploratory Pharmacokinetic Study of Virgin Coconut Oil (VCO) N/A